Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Portfolio Pulse from Vandana Singh
Seagen Inc and Genmab A/S have released positive topline data from their Phase 3 innovaTV 301 global trial for Tivdak in recurrent or metastatic cervical cancer patients. The study met its primary endpoint of overall survival. The results are intended to support the U.S. accelerated approval and global regulatory applications for Tivdak. The innovaTV 301 China extension study, in collaboration with Zai Lab Limited, has been initiated and continues to enroll patients.
September 05, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive trial results for Tivdak could lead to accelerated approval and increased sales, potentially boosting Genmab's stock.
Positive trial results often lead to increased investor confidence and potential stock price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Positive trial results for Tivdak could lead to accelerated approval and increased sales, potentially boosting Seagen's stock.
Positive trial results often lead to increased investor confidence and potential stock price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zai Lab Limited's collaboration with Seagen and Genmab on the innovaTV 301 China extension study could potentially boost its stock.
Collaborations on successful trials can lead to increased investor confidence and potential stock price increases.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80